Physician profile
Sunil A Patel
NPI 1588715916
$12,008.25
in general payments reported to CMS, 2019-2025
87 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,503 · 2020: $1,579 · 2021: $1,357 · 2022: $2,299 · 2023: $2,116 · 2024: $1,804 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,253 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,253.40 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $886.24 | 2019-2023 | Lumakras, Vectibix, Nplate |
| Pfizer INC. | $758.13 | 2019-2024 | |
| Coherus Oncology, INC. | $695.47 | 2020-2025 | Loqtorzi |
| Merck Sharp & Dohme LLC | $628.98 | 2019-2024 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $585.19 | 2019-2024 | |
| Incyte Corporation | $475.09 | 2019-2024 | Monjuvi, Jakafi |
| Janssen Biotech, INC. | $453.80 | 2019-2025 | Carvykti, Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals LP | $442.36 | 2019-2024 | Imfinzi, Enhertu, Calquence |
| Abbvie INC. | $376.92 | 2019-2024 | |
| Celgene Corporation | $319.98 | 2019-2024 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $310.50 | 2019-2024 | Tecentriq, Venclexta, Columvi |
| E.R. Squibb & Sons, L.L.C. | $308.68 | 2019-2024 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $304.30 | 2019-2024 | Fruzaqla, Ninlaro, Vonvendi |
| Genzyme Corporation | $267.34 | 2019-2024 | |
| Lilly USA, LLC | $265.59 | 2019-2024 | Verzenio, Jaypirca |
Show all 84 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.